Evidence mapPaperPMID 31430977Full record

ReviewInternational journal of molecular sciences2019

Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders.

Maria João Meneses, Regina Silvestre, Inês Sousa-Lima, Maria Paula Macedo

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 104 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Paraoxonase (International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Role of oxidative stress in prediabetes development.Biochemistry and biophysics reports · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Transcriptomic analysis of Paraoxonase 1 expression in hepatocellular carcinoma and its potential impact on tumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Maria João MenesesCEDOC-Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal.
Regina SilvestreCEDOC-Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal.
Inês Sousa-LimaCEDOC-Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal.
Maria Paula MacedoCEDOC-Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1150-082 Lisbon, Portugal. paula.macedo@nms.unl.pt.
Associacao Protectora dos Diabeticos de Portugal · PTUniversidade Nova de Lisboa · PT

Funding

European Commission Marie Skłodowska-Curie Actions H2020 grant agreements no. 722619 and no. 734719Fundação para a Ciência e a Tecnologia to Maria J. Meneses (PD/BD/114256/2016); M. Paula Macedo (PTDC/DTP-EPI/0207/2012, PTDC/BIM-MET/2115/2014 and PTDC/BIM-MET/4265/2014); and iNOVA4Health (UID/Multi/04462/2013)Sociedade Portuguesa de Diabetologia GIFT 2018
6 · The paper itself

Abstract

Metabolic disorders are characterized by an overall state of inflammation and oxidative stress, which highlight the importance of a functional antioxidant system and normal activity of some endogenous enzymes, namely paraoxonase-1 (PON1). PON1 is an antioxidant and anti-inflammatory glycoprotein from the paraoxonases family. It is mainly expressed in the liver and secreted to the bloodstream, where it binds to HDL. Although it was first discovered due to its ability to hydrolyze paraoxon, it is now known to have an antiatherogenic role. Recent studies have shown that PON1 plays a protective role in other diseases that are associated with inflammation and oxidative stress, such as Type 1 and Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease. The aim of this review is to elucidate the physiological role of PON1, as well as the impact of altered PON1 levels in metabolic disorders.

Indexed as

Lipid MetabolismAnimalsAryldialkylphosphataseDisease ProgressionGlucoseHomeostasisHumansInflammationMetabolic DiseasesOxidative StressAryldialkylphosphataseGlucosePON1 protein, humandiabetes mellitusglucoseinsulin resistanceNAFLDobesityPON1

Identifiers

PMID31430977
PMCPMC6720961
OpenAlexW2969936136

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.